Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2010 / Cilt: 44 - Sayı: 3

Hypophosphatemic osteomalacia in neurofibromatosis type 1: Insufficiency fractures

Nörofibromatozis tip 1’de hipofosfatemik osteomalazi: Yetmezlik kırıkları

Pages
160–163
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition to systemic examination, measurement of blood phosphorus level and bone mineral density must be done in order to prevent severe morbidities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neurofibromatosis is a group of clinically related systemic disorders characterized by autosomal dominant inheritance.
📊
Key Findings & Data:Hypophosphatemia may rarely develop due to phosphorus loss in the urine in a patient with neurofibromatosis type 1.
💡
Conclusion & Impact:In addition to systemic examination, measurement of blood phosphorus level and bone mineral density must be done in order to prevent severe morbidities.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neurofibromatosis is a group of clinically related systemic disorders characterized by autosomal dominant inheritance. Hypophosphatemia may rarely develop due to phosphorus loss in the urine in a patient with neurofibromatosis type 1. We present here a 42-year-old male patient with neurofibromatosis type 1, who has two-year history of bone pain and fatigue. Hypoproteinemia, very low blood phosphorus level, significant reduction in bone mineral density, and insufficiency fractures of the proximal femurs and left fibula were detected. It was considered that hypophosphatemic osteomalacia led to stress fractures. The fractures were sufficiently healed with bisphosphonate, vitamin D, calcium treatment and phosphorus-rich diet. The blood phosphorus level of the patient approached approximately the normal limits. Long-lasting spinal, arm and leg pain in patients with neurofibromatosis type 1 must be carefully followed. It should be kept in mind that hypophosphatemic osteomalacia may occur in these patients. In addition to systemic examination, measurement of blood phosphorus level and bone mineral density must be done in order to prevent severe morbidities.

Özet

Nörofibromatozis, otozomal dominant geçiş gösteren, birbiri ile bağlantılı bir grup sistemik bozukluklar topluluğudur. Nadiren nörofibromatozis tip 1’de idrarda fosfor kaybına bağlı olarak hipofosfatemi gelişebilmektedir. İki yıldır süregelen kemik ağrıları ve yorgunluk öyküsü olan 42 yaşında nörofibromatozis tip 1’li erkek hasta sunulmaktadır. Hastada hipoproteinemi, çok düşük kan fosfor seviyesi, kemik mineral yoğunluğunda belirgin azalma, bilateral proksimal femurda ve sol fibulada yetmezlik kırıkları tesbit edildi. Hipofosfatemik osteomalazinin stres kırıklarına yol açtığı anlaşıldı. Bifosfonat, vitamin D, kalsiyum tedavisi ve fosfordan zengin diyet ile kırıklarda yeterli iyileşme görüldü. Hastanın kan fosfor seviyesi normal sınırlara yaklaştı. Nörofibromatozis tip 1’li hastaların uzun süreli omurga, kol ve bacak ağrıları dikkatle izlenmelidir. Bu hastalarda hipofosfatemik osteomalazi olabileceği akla gelmelidir. Ciddi morbiditeleri önlemek için sistemik muayeneye ilaveten kan fosfor seviyesinin ve kemik mineral yoğunluğunun ölçümü yapılmalıdır.

🔖

Cite This Article

ÇENESİZOĞLU, E., BEYCİOĞLU, H., YILMAZ, A. (2022). Hypophosphatemic osteomalacia in neurofibromatosis type 1: Insufficiency fractures. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 44 - Sayı: 3, 160–163. https://ajindex.com/articles/622016

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC: Dermatology. 2nd ed. Berlin, Springer-Verlag 2000;840-4
  2. Fitzpatrick TB, Johnson RA, Wolff K, Polano MK, Suurmond D: Color atlas and synopsis of clinical dermatology. 3rd ed. New York, Mc Graw-Hill 1997;458-62
  3. Abdel–Wanis ME, Kawahara N: Hypophosphatemic osteomalacia in neurofibromatosis 1: hypotheses for pathogenesis and higher incidence of spinal deformity. Med Hypotheses 2002;59:183-5
  4. Saville PD, Nassim JR, Stevenson FH, Mulligan L,Carey M: Osteomalacia in Von Recklinghausen’s neurofibromatosis. Br Med J 1955;28:1311-3
  5. Tonsgard JH: Clinical manifestation and management of neurofibromatosis type 1. Semin Pediatr Neurol 2006;13:2-7
  6. Kaymak Y, Yüksel N, Karbulut AN, Ekflioglu M: Nörofibromatozis: olgu sunumu. Turkiye Klinikleri J Med Sci 2004;24:702-6
  7. Abdel-Wanis ME, Kawahara N: Bone devolopment in neurofibromatosis 1. Med Hypotheses 2003;60:459-62
  8. Brunetti-Pierri N, Doty SB, Hicks J et al: Generalized metabolic bone disease in neurofibromatosis type 1. Molecular Genetics and Metabolism 2008;94:105-11
  9. Gürkan V, Özger H, Berkel T: Tip 1 nörofibromatozise bağlı ossifiye subperiostal hematom: iki olgu sunumu. Acta Orthop Traumatol Turc 2007;41:397-400
  10. Uysal AR: Osteomalazi. Turkiye Klinikleri J Endocrin 2004;2: 146-54
  11. Fayad LM, Kamel IR, Kawamoto S, Bluemke DA, Frassica FJ, Fishman EK: Distinguishing stress fractures from pathologic fractures: a multimodality approach. Skeletal Radiol 2005;34:245-59
  12. Soubrier M, Dubost JJ, Boisgard S et al: Insufficiency fracture. A survey of 60 cases review of the literature. Joint Bone Spine 2003;70:209-18.